Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Combination treatment with disitamab vedotin (DV) and toripalimab results in positive objective response rates (ORR) and overall survival (OS), with an acceptable safety profile, in HER2-unselected locally advanced or metastatic urothelial carcinoma (mUC) patients, as shown by the results of a phase Ib/II study.

DV plus toripalimab shows promise in metastatic urothelial carcinoma

ICIs plus statins may extend survival in cancer patients

Treatment with statins combined with immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors, is associated with improved survival in cancer patients, according to a study.

ICIs plus statins may extend survival in cancer patients

NAC protects against chemo-induced neuropathy

19 Mar 2025

Treatment with oral N-acetylcysteine (NAC) 1,200 mg/day does not result in a significant reduction in the incidence or severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer, a recent study has shown.

NAC protects against chemo-induced neuropathy

19 Mar 2025

Managing advanced colorectal cancer with robotic surgery

19 Mar 2025 bởi

In colorectal cancer, the traditional method for removing the tumour is open surgery. However, the surgical treatment landscape has evolved over the years and transitioned to embrace the utilization of minimally invasive approaches such as laparoscopic or keyhole surgery and the use of robotics.

Managing advanced colorectal cancer with robotic surgery

19 Mar 2025

Probiotics help relieve chemo-induced diarrhoea

The use of probiotics leads to a significant reduction in chemotherapy-related diarrhoea, suggesting its potential as supportive care agent in oncology, according to a study.

Probiotics help relieve chemo-induced diarrhoea

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

Treatment with the combination of the immune checkpoint inhibitor tislelizumab plus low-dose nab-paclitaxel exerts promising antitumour activity in patients with very high risk non–muscle-invasive bladder cancer who are ineligible for or decline radical cystectomy, according to the results of the phase II TRUCE-02 trial.

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

Family history of CRC ups risk of adenoma, neoplasia

17 Mar 2025 bởi

Individuals with a family history of colorectal cancer (CRC) are at greater risk of developing adenoma, nonadvanced adenoma (NAA), advanced adenoma (AA), and advanced neoplasia (AN), reveals a study.

Family history of CRC ups risk of adenoma, neoplasia

17 Mar 2025

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

Using tranexamic acid (TXA) appears to lessen blood loss and the need for perioperative blood transfusion (PBT) without increasing the risk of venous thromboembolism (VTE) in patients with bladder cancer undergoing radical cystectomy, reports a study.

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

Original New Drug Application Approvals by US FDA (16-28 February 2025)

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)